Continent with an app - from research to implementation of mobile apps for self-treatment of urinary leakage
| Reference number | |
| Coordinator | eContinence AB |
| Funding from Vinnova | SEK 200 000 |
| Project duration | May 2022 - October 2023 |
| Status | Completed |
| Venture | Medtech4Health: Competence Enhancement in SME |
| Call | Medtech4Health: Skills enhancement in small businesses 2022 |
Important results from the project
Urinary leakage is a common problem, every fourth woman and every eighth man have problems. The Tät® app is based on self-treatment of urinary leakage and is one of the very few apps that has been evaluated in research regarding effectiveness and health economics. The goal for eContinence AB is to further develop the app and be able to provide it to as many people as possible in a safe and secure way as a CE-marked product.
Expected long term effects
The app is now further developed and launched as a class I medical device via Google and Apple as a Basic and Premium app respectively. It is now available in Sweden, Norway, Denmark, Finland, Great Britain, Spain, Germany and Austria. It is available in 8 languages. Currently, there are approximately 70,000 people who have the app installed. We now have a scalable product for a global market and are working further to develop the app as a licensed product in collaboration with health companies.
Approach and implementation
The quality management system and technical documentation have been updated with support of consultants and workshop trainings. The app could be CE-marked within the EU in 2022 and later also in Norway and Great Britain. The Tät® app has been further developed and launched commercially in 2022. We continue our work on a version of the app aimed for healthcare companies.